Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by Rosmorducon Mar 04, 2020 8:50am
118 Views
Post# 30764586

RE:RE:RE:RE:RE:alex russ is on bnn at 6 today

RE:RE:RE:RE:RE:alex russ is on bnn at 6 todayEven Alex is 100% confident that there was something wrong with those 5 sites where cornstarch yielded the same placebo effect as CAPRE. Not only does that sound funny/odd, but how is that CAPRE's fault when CAPRE worked like a charm???

There is an old saying...when something doesn't make sense, it's not true. 

I view the present stock price as a huge buying opportunity. 10 years of research and phase 1 and phase 2 shows that CAPRE is a blockbuster drug that will revolutionize heart disease and perhaps even diabetes. 

All this will get sorted out soon, unless a big pharma steps in here and buys ACST outright which is very possible in my opinion. 


Bullboard Posts